SpotitEarly Enters U.S. Market with $20M+ to Revolutionize At-Home Early Cancer Detection

The Company’s Cancer Detection Technology has Achieved a 94 Percent Accuracy Rate, Attracting Top Investors, Researchers, and Academic Medical Centers

SpotitEarly, a biotech startup focused on transforming cancer screening by harnessing the power of artificial intelligence and canines to analyze volatile organic compounds (VOCs) in breath samples and detect cancer at its earliest stages, today officially launched in the U.S. market having raised $20.3 million in funding. This funding helps SpotitEarly scale its U.S. presence and strengthen its cancer detection technology, which achieved a 94 percent accuracy rate in a two-year clinical trial including 1400 individuals, published in Nature’s Scientific Reports. The at-home test will be made commercially available in the U.S. in 2026.

The company has attracted investments from top venture capital firms and angel investors, including Hanaco VC, Menomedin VC, Jeff Swartz (former CEO of Timberland), Avishai Abrahami (CEO of Wix.com), and others. In addition to private funding, SpotitEarly has also been awarded several grants, most notably from the BIRD Foundation, a binational foundation that funds joint industrial research and development between American and Israeli companies.

With cancer care costs in the U.S. expected to reach $245 billion by 2030, SpotitEarly’s bio-hybrid approach to cancer screening offers a timely solution. The company’s proprietary method will offer a simple at-home breath test for the four most common types of cancer - breast, colorectal, prostate, and lung. Using an innovative diagnostic process that taps into the powerful scent detection of trained canines, analyzed by its LUCID AI technology, which monitors and collects thousands of data points on the dog's physical and behavioral signals, SpotitEarly effectively addresses the urgent need for advancements in early detection and prevention of cancer.

“Early detection can increase survival rates to as high as 99 percent and save billions in treatment costs to the medical system,” said Alon Lifshitz, Founding Partner at Hanco Ventures. “That’s exactly what makes SpotitEarly stand out. Today’s screening methods are often invasive, expensive, and uncomfortable - barriers that limit adoption. SpotitEarly is filling a critical gap in preventative healthcare with a solution that is non-invasive, affordable, and designed to help more people benefit from early detection.”

To further advance its mission of convenient, accessible cancer screenings, SpotitEarly has also appointed U.S.-based advisors to its scientific board. These include Dr. David Sidransky, a leading expert and pioneer in the molecular genetic detection of cancer, Jonathan Fleming, senior lecturer at the Massachusetts Institute of Technology (MIT) and highly experienced medtech entrepreneur and investor as well as Dr. Len Lichtenfeld, former deputy Chief Medical Officer of the American Cancer Society, who will now serve as SpotitEarly’s Chief Medical Officer. These relationships will be pivotal as SpotitEarly expands its research partnerships with major U.S.-based academic medical centers, such as the University of Pennsylvania.

“While there has been movement from emerging tech companies that have shown great promise for transforming the way we screen and detect cancer, they’ve lacked accessibility and precision,” said Shlomi Madar, Ph.D., CEO of SpotitEarly. ”The opportunity to bring SpotitEarly’s innovative tech and dynamic approach to the U.S., and to drastically improve how we conquer a complex and persistent disease that takes the lives of millions of Americans each year, is both a great honor and responsibility.”

In tandem with its launch into the U.S. Market, SpotitEarly has opened its Series A funding round under Regulation D (Reg D), offering accredited investors the opportunity to support the company’s next phase of growth. For more details on SpotitEarly and how to invest in the Series A round, please visit spotitearly.com/invest.

This press release should not be construed as an offer to buy the securities of SpotitEarly. Any offering of the securities of SpotitEarly will only be made by means of a Private Offering Memorandum.

About SpotitEarly

SpotitEarly aims to revolutionize cancer screening with its breath-based early detection test for multiple types of cancer. Powered by a proprietary bio-AI hybrid platform, the test will integrate advanced artificial intelligence with nature's unparalleled detection abilities to identify cancer-associated volatile organic compounds (VOCs) at early stages. By combining AI with the scent-based biometrics of trained canines, SpotitEarly will introduce a simple breath collection process involving a face mask kit. A diverse, multidisciplinary team of medical professionals, scientists, and technology experts collaborate seamlessly to bring this innovative solution to life. Subject to regulatory approval, SpotitEarly aims to improve access to cancer screening, enhance early detection rates, and significantly boost survival outcomes. For more information, visit our website or follow SpotitEarly on LinkedIn, Facebook, and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250515336844/en/